Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs

Jhi Joung Wang, K. C. Sung, Oliver Yoa Pu Hu, Chih Hui Yeh, Jia You Fang

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

This study investigates the submicron lipid emulsion as a potential parenteral drug delivery system for nalbuphine and its ester prodrugs. Submicron emulsions were prepared using egg phospholipid as the main emulsifier, various co-emulsifiers were also incorporated, including Brij 30, Brij 98, and stearylamine. Squalene as the oil phase formed stable emulsions with small particles. Drug release was affected by incorporating various co-emulsifiers and drugs with various lipophilicity. The loading of nalbuphine into lipid emulsions resulted in the slower and sustained release of nalbuphine. Lipid emulsions containing Brij 98 could further enhance the release of prodrugs as compared to the aqueous solution (control) especially for nalbuphine enanthate (NAE). Hemolysis caused by the interaction between erythrocytes and lipid emulsions was investigated. Brij 30 and Brij 98 could shield the hemolytic activity of phospholipids in the oil/water interface, decreasing the acute toxicological potential of the emulsions. The in vivo analgesic activity of various emulsions was examined by a cold ethanol tail-flick test. The analgesic duration and potency were significantly increased by incorporating nalbuphine and NAE into Brij 98-containing emulsions. There was no need for nalbuphine benzoate (NAB) to show a controlled delivery manner by encapsulating into emulsions, since NAB itself could prolong the analgesic duration of nalbuphine due to the slow enzyme degradation. The in vivo analgesic activity correlated well to the profiles of in vivo pharmacokinetic profiles. The study demonstrates the feasibility of using submicron lipid emulsion as the parenteral drug delivery system for nalbuphine and its prodrugs.

Original languageEnglish
Pages (from-to)140-149
Number of pages10
JournalJournal of Controlled Release
Volume115
Issue number2
DOIs
Publication statusPublished - Oct 10 2006
Externally publishedYes

Fingerprint

Nalbuphine
Prodrugs
Drug Delivery Systems
Emulsions
Lipids
Analgesics
Heptanoates
Benzoates
Phospholipids
Oils
Squalene
Feasibility Studies
Hemolysis
Toxicology
Ovum

Keywords

  • Controlled release
  • Drug delivery
  • Lipid emulsions
  • Nalbuphine
  • Prodrugs

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. / Wang, Jhi Joung; Sung, K. C.; Hu, Oliver Yoa Pu; Yeh, Chih Hui; Fang, Jia You.

In: Journal of Controlled Release, Vol. 115, No. 2, 10.10.2006, p. 140-149.

Research output: Contribution to journalArticle

Wang, Jhi Joung ; Sung, K. C. ; Hu, Oliver Yoa Pu ; Yeh, Chih Hui ; Fang, Jia You. / Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs. In: Journal of Controlled Release. 2006 ; Vol. 115, No. 2. pp. 140-149.
@article{2b15d98dedbe4afb9ba58b5e6feea196,
title = "Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs",
abstract = "This study investigates the submicron lipid emulsion as a potential parenteral drug delivery system for nalbuphine and its ester prodrugs. Submicron emulsions were prepared using egg phospholipid as the main emulsifier, various co-emulsifiers were also incorporated, including Brij 30, Brij 98, and stearylamine. Squalene as the oil phase formed stable emulsions with small particles. Drug release was affected by incorporating various co-emulsifiers and drugs with various lipophilicity. The loading of nalbuphine into lipid emulsions resulted in the slower and sustained release of nalbuphine. Lipid emulsions containing Brij 98 could further enhance the release of prodrugs as compared to the aqueous solution (control) especially for nalbuphine enanthate (NAE). Hemolysis caused by the interaction between erythrocytes and lipid emulsions was investigated. Brij 30 and Brij 98 could shield the hemolytic activity of phospholipids in the oil/water interface, decreasing the acute toxicological potential of the emulsions. The in vivo analgesic activity of various emulsions was examined by a cold ethanol tail-flick test. The analgesic duration and potency were significantly increased by incorporating nalbuphine and NAE into Brij 98-containing emulsions. There was no need for nalbuphine benzoate (NAB) to show a controlled delivery manner by encapsulating into emulsions, since NAB itself could prolong the analgesic duration of nalbuphine due to the slow enzyme degradation. The in vivo analgesic activity correlated well to the profiles of in vivo pharmacokinetic profiles. The study demonstrates the feasibility of using submicron lipid emulsion as the parenteral drug delivery system for nalbuphine and its prodrugs.",
keywords = "Controlled release, Drug delivery, Lipid emulsions, Nalbuphine, Prodrugs",
author = "Wang, {Jhi Joung} and Sung, {K. C.} and Hu, {Oliver Yoa Pu} and Yeh, {Chih Hui} and Fang, {Jia You}",
year = "2006",
month = "10",
day = "10",
doi = "10.1016/j.jconrel.2006.07.023",
language = "English",
volume = "115",
pages = "140--149",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Submicron lipid emulsion as a drug delivery system for nalbuphine and its prodrugs

AU - Wang, Jhi Joung

AU - Sung, K. C.

AU - Hu, Oliver Yoa Pu

AU - Yeh, Chih Hui

AU - Fang, Jia You

PY - 2006/10/10

Y1 - 2006/10/10

N2 - This study investigates the submicron lipid emulsion as a potential parenteral drug delivery system for nalbuphine and its ester prodrugs. Submicron emulsions were prepared using egg phospholipid as the main emulsifier, various co-emulsifiers were also incorporated, including Brij 30, Brij 98, and stearylamine. Squalene as the oil phase formed stable emulsions with small particles. Drug release was affected by incorporating various co-emulsifiers and drugs with various lipophilicity. The loading of nalbuphine into lipid emulsions resulted in the slower and sustained release of nalbuphine. Lipid emulsions containing Brij 98 could further enhance the release of prodrugs as compared to the aqueous solution (control) especially for nalbuphine enanthate (NAE). Hemolysis caused by the interaction between erythrocytes and lipid emulsions was investigated. Brij 30 and Brij 98 could shield the hemolytic activity of phospholipids in the oil/water interface, decreasing the acute toxicological potential of the emulsions. The in vivo analgesic activity of various emulsions was examined by a cold ethanol tail-flick test. The analgesic duration and potency were significantly increased by incorporating nalbuphine and NAE into Brij 98-containing emulsions. There was no need for nalbuphine benzoate (NAB) to show a controlled delivery manner by encapsulating into emulsions, since NAB itself could prolong the analgesic duration of nalbuphine due to the slow enzyme degradation. The in vivo analgesic activity correlated well to the profiles of in vivo pharmacokinetic profiles. The study demonstrates the feasibility of using submicron lipid emulsion as the parenteral drug delivery system for nalbuphine and its prodrugs.

AB - This study investigates the submicron lipid emulsion as a potential parenteral drug delivery system for nalbuphine and its ester prodrugs. Submicron emulsions were prepared using egg phospholipid as the main emulsifier, various co-emulsifiers were also incorporated, including Brij 30, Brij 98, and stearylamine. Squalene as the oil phase formed stable emulsions with small particles. Drug release was affected by incorporating various co-emulsifiers and drugs with various lipophilicity. The loading of nalbuphine into lipid emulsions resulted in the slower and sustained release of nalbuphine. Lipid emulsions containing Brij 98 could further enhance the release of prodrugs as compared to the aqueous solution (control) especially for nalbuphine enanthate (NAE). Hemolysis caused by the interaction between erythrocytes and lipid emulsions was investigated. Brij 30 and Brij 98 could shield the hemolytic activity of phospholipids in the oil/water interface, decreasing the acute toxicological potential of the emulsions. The in vivo analgesic activity of various emulsions was examined by a cold ethanol tail-flick test. The analgesic duration and potency were significantly increased by incorporating nalbuphine and NAE into Brij 98-containing emulsions. There was no need for nalbuphine benzoate (NAB) to show a controlled delivery manner by encapsulating into emulsions, since NAB itself could prolong the analgesic duration of nalbuphine due to the slow enzyme degradation. The in vivo analgesic activity correlated well to the profiles of in vivo pharmacokinetic profiles. The study demonstrates the feasibility of using submicron lipid emulsion as the parenteral drug delivery system for nalbuphine and its prodrugs.

KW - Controlled release

KW - Drug delivery

KW - Lipid emulsions

KW - Nalbuphine

KW - Prodrugs

UR - http://www.scopus.com/inward/record.url?scp=33749835512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749835512&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.07.023

DO - 10.1016/j.jconrel.2006.07.023

M3 - Article

C2 - 16959357

AN - SCOPUS:33749835512

VL - 115

SP - 140

EP - 149

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 2

ER -